HWHG(SH:600079) Shang Hai Zheng Quan Bao·2025-08-25 20:57Core Viewpoint - The company has received approval for a new indication for its injectable remimazolam, which is expected to expand its market usage and positively impact sales [1][2]. Group 1: Drug Registration Details - The drug name is injectable remimazolam, with registration numbers 2025S02529 and 2025S02530 [1]. - The drug is classified as a chemical drug of category 2.4 and is produced by Yichang Renfu Pharmaceutical Co., Ltd., in which the company holds an 80% stake [1][2]. - The new indication approved is for use as a sedative during mechanical ventilation in intensive care [1][2]. Group 2: Development and Market Impact - The injectable remimazolam was co-developed with Germany's PAION and is a novel benzodiazepine derivative [2]. - The company invested approximately RMB 20 million in the project, and the projected market sales for 2024 are around RMB 250 million [2]. - The approval of the new indication is expected to broaden the product's application, potentially leading to increased revenue for the company [2].